The ICD-10-CM (International Classification of Diseases, Tenth Revision, Clinical Modification) is a system used by physicians and other healthcare providers to classify and code all diagnoses, symptoms and procedures recorded in conjunction with hospital care in the United States.
Search the full ICD-10 catalog by:
Why ICD-10 codes are important
ICD-10 code D47. 3 for Essential (hemorrhagic) thrombocythemia is a medical classification as listed by WHO under the range - Neoplasms .
Thrombocythemia refers to a high platelet count that is not caused by another health condition. This condition is sometimes called primary or essential thrombocythemia. Thrombocytosis refers to a high platelet count caused by another disease or condition.
Essential thrombocythemia is a type of chronic myeloproliferative disorder. That means your bone marrow, the spongy tissue inside your bones, makes too many of a certain type of cell. In the case of essential thrombocythemia, the bone marrow makes too many cells that create platelets.
Essential thrombocythaemia (ET) is a rare blood disorder that causes a high number of blood cells called platelets to form. These are blood cells involved in blood clotting. Thrombo means clotting and cythaemia relates to blood cells. It is also known as primary thrombocythaemia or essential thrombocytosis.
Primary thrombocytosis (or essential thrombocythemia) is a single disease entity, with unique clinical characteristics. Thrombocytopenia is the medical term for a low blood platelet count. Platelets (thrombocytes) are colorless blood cells that play an important role in blood clotting.
Abstract. Essential thrombocythemia patients develop acute myeloid leukemia (AML) at a rate of 1-4% during a median follow-up of 7-10 years. The risk increases with advanced age, anemia, platelet count ≥ 1000 × 10(9)/l, the presence of ≥ 2 somatic mutations and after the first decade of diagnosis.
Essential thrombocythemia (ET) is one of a related group of blood cancers known as “myeloproliferative neoplasms” (MPNs) in which cells in the bone marrow that produce the blood cells develop and function abnormally.
Even if your specific medical condition isn't listed, you may still be eligible. (Essential thrombocythemia and polycythemia vera, for example, are not specifically listed by name.) You must be unable to do any work you did previously. If you're applying for SSI, a past work history is not necessary.
The life expectancy of patients with essential thrombocytosis (primary thrombocythemia) is nearly that of the healthy population. Median survival is approximately 20 years. For patients younger than age 60 years, median survival is 33 years.
If your blood count is above 450,000 platelets per microliter of blood, your doctor will look for an underlying condition. He or she will rule out all other causes of high platelet counts to confirm a diagnosis of essential thrombocythemia.
[4] According to the World Health Organization, essential thrombocytosis is a disease that occurs when the platelet count is more than 450000 with the presence of Janus kinase 2 (JAK2), Calreticulin (CALR) or myeloproliferative leukemia virus oncogene (MPL) mutation, lacking clonal or reactive causes.
Very few papers are presently available on triple-negative ET, which is basically described as an indolent disease with a low incidence of vascular events, differently from triple-negative PMF, which is an aggressive myeloid neoplasm, with a significantly higher risk of leukemic evolution (27, 28).
ICD-9-CM 238.71 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 238.71 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).
With a routine blood test my life changed. I had been having severe migraine headaches and I had never had even small headaches really so my Dr. made the decision to test my blood from that to a hematologist and more blood work I was diagnosed. My bl...